Recently, Wiley, a renowned international academic publishing group, officially announced the results of the "Wiley China High Contribution Author Award" for the third quarter of 2025. Our company's research team's paper, "AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists," published in the top international journal *Advanced Science*, stood out from numerous outstanding achievements and successfully won this honor due to its exceptional academic impact and high international attention!

The "Wiley China Outstanding Contribution Author Award" is an honorary award established by Wiley China in response to the national "15th Five-Year Plan" for talent development and innovation-driven strategy. It is awarded through rigorous selection in high-level journals widely recognized by Chinese scholars and aims to recognize Chinese scientific research forces that have made outstanding contributions to promoting global scientific and technological progress.

Since its publication, the award-winning paper has been downloaded a total of 3,292 times as of January 31, 2026. It ranks among the top articles published by Chinese authors in the third quarter of 2025 in the journal Advanced Science. It immediately attracted widespread attention from scholars around the world after its publication, fully demonstrating our company's innovative strength and international influence in the field of AI drug design.

AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists

This research addresses the industry pain points of low success rates, long development cycles, and high costs associated with traditional peptide drug design. It innovatively combines deep learning protein design with functional screening to construct a highly efficient AI-powered peptide drug design platform. The research team designed 10,000 novel GLP-1 receptor agonist sequences and precisely identified 60 candidate peptides that met the requirements for stability, efficacy, and diversity through virtual functional screening, achieving an in vitro validation success rate of up to 52%.

Even more groundbreaking is the fact that in vivo experiments have shown that some candidate peptides have a half-life three times that of smegglutinin. The entire design and screening process can be completed within two weeks, significantly shortening the traditional drug development cycle and providing a completely new technological pathway for the treatment of metabolic diseases.

This award is a high recognition of the innovation capabilities and academic level of our company's research team, and also a significant achievement reflecting the company's commitment to a technology innovation-driven development strategy. In the future, we will continue to deepen our basic research and technological innovation, strengthen international academic exchanges and cooperation, and contribute even more to promoting the globalization of China's scientific and technological innovation!

About Wiley